A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative coli

van Deventer, S. J. H.; Tami, J. A.; Wedel, M. K.
November 2004
Gut;Nov2004, Vol. 53 Issue 11, p1646
Academic Journal
Objective: To evaluate the safety and efficacy of an enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule, after 1, 3, and 6 months. Methods: This was a randomised, placebo controlled, double blind, escalating dose multicentre study in 40 patients with mild to moderately active distal ulcerative colitis (disease activity index (DAI) 4–10). Patients were assigned to four dosing cohorts of 10 patients each (eight active, two placebo). Each patient received 60 ml of alicaforsen enema (0.1, 0.5, 2, or 4 mg/ml or placebo) once daily for 28 consecutive days. Safety and efficacy (DAI and clinical activity index) scores were evaluated up to six months after initiation of dosing. Results: At day 29, alicaforsen enema resulted in dose dependent improvement in DAI (overall p = 0.003). Alicaforsen 4 mg/ml improved DAI by 70% compared with the placebo response of 28% (p = 0.004). Alicaforsen 2 and 4 mg/ml improved DAI status by 72% and 68% compared with a placebo response of 11.5% at month 3 (p = 0.016 and 0.021, respectively). Specifically, DAI improved from 5.6 to 1.6 and from 6.3 to 2.5 in the 2 and 4 mg/ml groups compared with placebo (7.5 to 6.1). None of the patients in the 4 mg/ml group compared with 4/8 placebo patients required additional medical or surgical intervention over baseline during the six month period after starting the enema treatment. The safety profile was favourable. Conclusions: Alicaforsen enema showed promising acute and long term benefit in patients with mild to moderate descending ulcerative colitis. Alicaforsen enemas had a favourable safety profile. These findings require verification in larger randomised controlled clinical trials.


Related Articles

  • Activity of Inducible and Neuronal Nitric Oxide Synthases in Colonic Mucosa Predicts Progression of Ulcerative Colitis. Menchén, Luis; Colón, Arturo L.; Madrigal, José L.M.; Beltrán, Luis; Botella, Sofía; Lizasoain, Ignacio; Leza, Juan C.; Moro, María A.; Menchén, Pedro; Cos, Enrique; Lorenzo, Pedro // American Journal of Gastroenterology;Sep2004, Vol. 99 Issue 9, p1756 

    OBJECTIVE: The present study analyzes inducible and neuronal nitric oxide synthase activity and expression in colonic mucosa of patients with ulcerative colitis, and correlates them with the progression of disease extent.METHODS: Thirty patients with ulcerative colitis were included. Synthases...

  • Cyclosporin Use in the Precolectomy Chronic Ulcerative Colitis Patient: A Community Experience and Its Relationship to Prospective and Controlled Clinical Trials. Kozarek, Richard; Bedard, Charles; Patterson, David; Justus, Peter; Sandford, Robert; Greene, Martin; Gelfand, Martin; Bredfeldt, James; Brentnall, Teri; Putnam, William; Silverman, Bruce; Brandabur, John; Hinds, John; Taubman, Gary; Wagner, Katherin; Driscoll, Richard; Mitchell, William // American Journal of Gastroenterology;Dec1995, Vol. 90 Issue 12, p2093 

    Objective: To define what effect seminal and controlled clinical trials have on practice patterns within a gastroenterological community. To define whether these practice patterns reproduce reported treatment methods and whether results comparable with those reported in such trials are noted...

  • An Open-Labeled, Randomized Study Comparing Systemic Interferon-α-2A and Prednisolone Enemas in the Treatment of Left-Sided Ulcerative Colitis. Madsen, S. M.; Schlichting, P.; Davidsen, B.; Nielsen, O. H.; Federspiel, B.; Riis, P.; Munkholm, P. // American Journal of Gastroenterology;Jun2001, Vol. 96 Issue 6, p1807 

    OBJECTIVE: The aim of this study was to compare the treatment efficacies of subcutaneous interferon-α-2A (IFN-α- 2A) injections versus prednisolone enemas in active left-sided ulcerative colitis in an open-labeled, randomized study. METHODS: Sixteen ulcerative colitis patients...

  • Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis - additional results from two controlled studies.  // Inflammatory Bowel Disease Monitor;2012, Vol. 12 Issue 3, p120 

    The article presents an analysis on data from clinical trials regarding the impact of mesalazine enemas in active distal ulcerative colitis. The analysis revealed that mesalazine enemas were effective to halt rectal bleeding equated with placebo and were effective at inducing full mucosal...

  • Two Years Later: The Impact of the EU Directive. Moulton, Brian // Applied Clinical Trials;Aug2006, Vol. 15 Issue 8, p46 

    The article provides some insights into the implications of the Clinical Trials Directive (CTD) of the European Union on European clinical research. The directive was initially designed to increase clinical trial patient protection, and prior to the implementation of CTD, there was European-wide...

  • No Plain English for UK Subjects. Laurence, Desmond // Applied Clinical Trials;Aug2006, Vol. 15 Issue 8, p94 

    The article comments on key controversies pertaining to the use of doublespeak in the patient recruitment process for clinical trials in Great Britain. Issues may arise if patients are not given sufficient information regarding the risks involved in clinical trials. The clinical trial sector in...

  • Evidence supporting platform-switching to preserve marginal bone levels not definitive. Stafford, Gary L // Evidence-Based Dentistry;Jun2012, Vol. 13 Issue 2, p56 

    Data sourcesMEDLINE, EMBASE, The Cochrane Oral Health Group's Trials Register, The Cochrane Central Register of Controlled Trials (CENTRAL), UK National Research Register, Australian New Zealand Clinical Trials Registry (ANZCTR), Database of Abstracts of Reviews of Effectiveness (DARE), ISI...

  • They're Dying to Get In. Bjerklie, David // Time;4/22/2002, Vol. 159 Issue 16, p56 

    Discusses the difficulty of being able to participate in clinical trials in medicine. Benefits of the trials, including substantial doctor-patient interaction; Idea that it is not just the terminally ill who benefit from the attention, but also medically neglected or poorly informed subjects...

  • CHAPTER 26: Design Principles and Their Application in Preventive Field Trials. Brown, C. Hendricks // Handbook of Drug Abuse Prevention: Theory, Science, & Practice;2003, p523 

    The article provides a framework for assessing the quality of a preventive field trial. Such a framework is useful for three purposes. First, research scientists can direct their attention to a limited number of essential elements in designing and implementing new preventive trials. Second,...


Read the Article


Sign out of this library

Other Topics